製造番号 | 種類 | 製品説明 | 構造 | 純度 | 特徴 |
---|---|---|---|---|---|
CD6-R52H9 | Rat | Rat B7-2 / CD86 Protein, His Tag | ![]() |
![]() ![]() |
|
CD6-H82F5 | Human | Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag™, premium grade | ![]() |
![]() ![]() |
|
CD6-M52H0 | Mouse | Mouse B7-2 / CD86 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD6-M5251 | Mouse | Mouse B7-2 / CD86 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD6-C5254 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag | ![]() |
![]() ![]() |
|
CD6-C52H5 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD6-H5223 | Human | Human B7-2 / CD86 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD6-H5257 | Human | Human B7-2 / CD86 Protein, Fc Tag, premium grade | ![]() |
![]() ![]() |
Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).
Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | United States | Rejection of renal transplantation | Bristol-Myers Squibb Pharma Eeig | 2011-06-15 | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection of organ transplantation; Delayed Graft Function; Rejection in heart transplantation; Kidney Failure, Chronic | Details |
Abatacept | BMS-188667SC; ONO-4164; BMS-188667; ONO-4164SC | Approved | Bristol-Myers Squibb Company | Orencia, 恩瑞舒 | United States | Arthritis, Rheumatoid | Bristol-Myers Squibb Company | 2005-12-23 | Colitis, Ulcerative; Arthritis; Common Variable Immunodeficiency; Uveitis; Cardiovascular Diseases; Asthma; Arthritis, Psoriatic; Sjogren-Larsson Syndrome; Urticaria; Scleroderma, Diffuse; Psoriasis; Takayasu Arteritis; Glomerulosclerosis, Focal Segmental; Anemia, Aplastic; Lupus Erythematosus, Systemic; Shwachman-Diamond Syndrome; Lung Diseases, Interstitial; Multiple Sclerosis; Nephrotic Syndrome; Muscular Diseases; Eye Diseases; Granulomatous Disease, Chronic; Lymphohistiocytosis, Hemophagocytic; Arthralgia; Myocarditis; Leukocyte-Adhesion Deficiency Syndrome; Inflammation; Vitiligo; Anemia, Sickle Cell; Thrombasthenia; Kostmann Syndrome; Crohn Disease; Behcet Syndrome; Graft vs Host Disease; Polychondritis, Relapsing; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Polymyositis; Wiskott-Aldrich Syndrome; Hematologic Diseases; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Alopecia Areata; Myositis; Dermatomyositis; Giant Cell Arteritis; Immunoglobulin G4 | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
ORCA-010 | ORCA-010 | Phase 2 Clinical | Orca Therapeutics Bv | Prostatic Neoplasms | Details |
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.